InMed Pharmaceuticals With Dr. Shane Johnson


InMed Pharmaceuticals With Dr. Shane Johnson today on Concierge For Better Living With Doc Rob only on The Cannabis Radio. InMed Pharmaceuticals is a global leader in the development, manufacturing, and commercialization of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness.

InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. InMed’s subsidiary, BayMedica, is producing a portfolio of rare cannabinoids as raw ingredients for your health and wellness products.

They have engineered bioidentical cannabinoids with high purity and consistency, and are free of THC. InMed currently manufactures the rare, minor cannabinoids cannabidivarin (CBDV), cannabichromene (CBC), and cannabicitran (CBT) which are available for wholesale purchase. They have started production of tetrahydrocannabivarin (THCV), with plans to have this highly sought, minor cannabinoid ready soon for inclusion in a wide variety of health and wellness products.

InMed’s rare cannabinoids are being applied across a spectrum of uses – from pharmaceutical development to wholesale sales to the consumer health and wellness sector. Their pharmaceutical programs include a Phase 2 clinical program in dermatology and a preclinical program in glaucoma. Our division, BayMedica, is the leading large batch producer of wholesale CBC (cannabichromene) cannabinoids for the consumer health and wellness industry.

In addition to CBC, InMed has initiated sales of cannabidivarin (CBDV) and cannabicitran (CBT) and has begun commercial-scale production of tetrahydrocannabivarin (THCV) to launch soon. Our portfolio also includes a growing library of patentable rare cannabinoid analogs for development.